Mirati Therapeutics, Inc.
MRTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.20 | -0.32 | -0.69 | -0.29 |
| FCF Yield | -22.58% | -5.24% | -2.79% | -3.09% |
| EV / EBITDA | -3.12 | -12.68 | -23.14 | -19.87 |
| Quality | ||||
| ROIC | -72.32% | -39.89% | -26.26% | -57.77% |
| Gross Margin | 95.18% | -605.48% | -2,134.28% | -5,383.24% |
| Cash Conversion Ratio | 0.77 | 0.67 | 0.76 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.45% | 178.57% | 1.20% | – |
| Free Cash Flow Growth | -44.36% | -44.47% | -84.82% | -112.59% |
| Safety | ||||
| Net Debt / EBITDA | 0.24 | 0.64 | 3.66 | 1.87 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.20 | -0.71 | -129.93 | -116.77 |
| Cash Conversion Cycle | -21,777.89 | -7,721.36 | -24.90 | 72.29 |